Physician profile
Isaac Levy
NPI 1871577221
$54,763.95
in general payments reported to CMS, 2019-2025
81 companies · $4,929 in 2025
The $4,929 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $8,870 · 2020: $4,395 · 2021: $7,365 · 2022: $7,992 · 2023: $5,943 · 2024: $15K · 2025: $4,929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Consulting Fee: $9,785 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000 · Travel and Lodging: $877 · Education: $641 · Long Term Medical Supply Or Device Loan: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,540.36 |
| Consulting Fee | $9,784.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
| Travel and Lodging | $877.22 |
| Education | $640.63 |
| Long Term Medical Supply Or Device Loan | $299.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $14,341.53 | 2019-2025 | Imfinzi, Tagrisso, Lynparza |
| Genzyme Corporation | $12,631.82 | 2019-2025 | |
| Pfizer INC. | $3,543.54 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $3,318.68 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Janssen Biotech, INC. | $2,356.82 | 2019-2025 | Erleada, Imbruvica, Darzalex |
| Novartis Pharmaceuticals Corporation | $2,329.35 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,345.54 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Rigel Pharmaceuticals, INC. | $971.58 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Astellas Pharma US INC | $958.82 | 2019-2025 | Xtandi, Padcev |
| Glaxosmithkline, LLC. | $930.07 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Celgene Corporation | $929.24 | 2019-2025 | Pomalyst, Reblozyl |
| Incyte Corporation | $732.89 | 2019-2025 | Jakafi |
| Beigene USA, INC. | $697.16 | 2020-2025 | Brukinsa |
| Eisai INC. | $657.83 | 2019-2025 | |
| Seagen INC. | $622.58 | 2019-2023 | Tivdak, Tukysa |
Show all 78 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $572.19 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $562.31 | 2021-2025 | Ultomiris |
| Lilly USA, LLC | $452.44 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Array Biopharma INC | $419.56 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Takeda Pharmaceuticals U.S.A., INC. | $405.47 | 2020-2025 | Alunbrig, Fruzaqla, Iclusig |
| Amgen INC. | $332.36 | 2019-2022 | |
| Exelixis INC. | $328.94 | 2019-2025 | Cabometyx |
| Genentech USA, INC. | $315.14 | 2019-2023 | Venclexta, Tecentriq |
| Myriad Genetic Laboratories, INC. | $304.80 | 2022-2025 | Myrisk |
| Daiichi Sankyo INC. | $284.71 | 2019-2025 | Enhertu, Datroway |
| Sobi, INC | $249.85 | 2022-2025 | |
| Epizyme, INC. | $243.97 | 2021-2023 | Tazverik |
| Bayer Healthcare Pharmaceuticals INC. | $237.50 | 2019-2025 | |
| Adaptive Biotechnologies Corporation | $236.84 | 2022-2025 | Clonoseq |
| Taiho Oncology, INC. | $216.13 | 2019-2025 | |
| Stemline Therapeutics INC. | $200.45 | 2023-2025 | Orserdu |
| Regeneron Healthcare Solutions, INC. | $196.95 | 2021-2024 | Libtayo |
| Pharmaessentia USA Corporation | $153.03 | 2024-2025 | Besremi |
| Dova Pharmaceuticals | $129.58 | 2019-2021 | |
| Mirati Therapeutics, INC. | $119.86 | 2023-2024 | Krazati |
| Karyopharm Therapeutics INC. | $110.52 | 2023-2024 | Xpovio |
| Gilead Sciences, INC. | $105.06 | 2019-2025 | Trodelvy |
| Janssen Scientific Affairs, LLC | $103.25 | 2023-2025 | Rybrevant, Akeega, Balversa |
| Sumitomo Pharma America, INC. | $102.02 | 2023-2025 | Orgovyx |
| Medtronic, INC. | $99.00 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $94.81 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $92.42 | 2022-2024 | Onivyde, Somatuline Depot |
| Deciphera Pharmaceuticals INC. | $89.90 | 2021-2022 | |
| Tempus Ai, INC | $85.43 | 2024-2025 | Xt Cdx |
| Pharmacyclics LLC, An Abbvie Company | $83.33 | 2021-2022 | |
| Myovant Sciences INC. | $78.82 | 2021-2022 | |
| Kite Pharma, INC. | $77.76 | 2021-2024 | Yescarta |
| Foundation Medicine, INC. | $73.94 | 2019-2023 | |
| Emd Serono, INC. | $71.60 | 2022-2024 | Bavencio |
| Geron Corporation | $69.89 | 2025 | Rytelo |
| Teva Pharmaceuticals USA, INC. | $67.55 | 2019 | |
| Caris Mpi, INC. | $66.52 | 2025 | Mi Cancer Seek |
| Servier Pharmaceuticals LLC | $65.21 | 2024-2025 | |
| Fennec Pharmaceuticals, INC. | $62.86 | 2024-2025 | Pedmark, Fyarro |
| Medtronic Vascular, INC. | $60.00 | 2019 | |
| Tersera Therapeutics LLC | $58.88 | 2024-2025 | Quzyttir, Zoladex |
| Verastem, INC. | $57.35 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $54.14 | 2023-2024 | Avastin, Neulasta, Neupogen |
| Partner Therapeutics, INC. | $49.40 | 2019-2020 | |
| Iovance Biotherapeutics, INC. | $46.19 | 2025 | Amtagvi |
| Tesaro, INC. | $45.88 | 2019 | |
| Legend Biotech USA INC. | $44.09 | 2025 | Carvykti |
| Cti Biopharma Corp. | $38.19 | 2023 | Vonjo |
| Helsinn Therapeutics (U.S.), INC. | $38.13 | 2019 | |
| Coherus Oncology, INC. | $37.61 | 2020 | |
| Blueprint Medicines Corporation | $36.63 | 2024 | Ayvakit |
| Aveo Pharmaceuticals, INC. | $36.15 | 2025 | |
| Morphosys, US INC. | $34.76 | 2023 | Monjuvi |
| Ge Healthcare | $32.43 | 2022 | |
| Pharmacosmos Therapeutics INC. | $24.81 | 2024 | Monoferric |
| Agios Pharmaceuticals, INC. | $23.95 | 2025 | Pyrukynd |
| Tg Therapeutics, INC. | $19.41 | 2021 | |
| Sanofi-Aventis U.S. LLC | $18.86 | 2020 | |
| Verity Pharmaceuticals INC. | $17.78 | 2022 | |
| Clovis Oncology, INC. | $16.86 | 2021 | |
| Jazz Pharmaceuticals INC. | $15.97 | 2021 | |
| Sun Pharmaceutical Industries INC. | $13.92 | 2024 | |
| Recordati_rare_diseases_inc. | $13.14 | 2024 | Sylvant |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$17,303.17 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isaac Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.